title: Effect of interferon alpha-2b on endometrioma cells in vitro.
abstract: OBJECTIVE
  To examine the effect of interferon alpha-2b on the growth of endometrioma cells and its effect on the DNA synthesis.
  
  
  METHODS
  Cells from four separate endometrioma cell lines were seeded into six-well plates in M199 medium containing increasing levels of interferon alpha-2b: 0 (control), 50, 100, 500, 1000, and 2000 U/mL. All cells were counted on days 0, 3, 6, and 9 in quadruplicate, and the counts were averaged for each condition. A second experiment was run to demonstrate the effect of short-term exposure of interferon alpha-2b on the growth of endometrioma cells in culture. In a separate experiment, cells from two endometriomas were plated in quadruplicate to evaluate the DNA synthesis. On day 3, 1000 and 4000 U/mL of interferon alpha-2b were added and run simultaneously with control (0 U/mL) wells. 3H-thymidine was added to each condition for 24 and 48 hours' incubation. Cells were then harvested and counted in a scintillation counter to study the 3H-thymidine uptake.
  
  
  RESULTS
  Interferon alpha-2b suppressed endometrioma cell growth in vitro. This effect increased with increasing concentrations of interferon alpha-2b (50-2000 U/mL) compared with the control (0 U/mL). The suppression of cell growth was statistically significant, but when interferon alpha-2b was removed from the culture cell growth increased. 3H-thymidine uptake by endometrioma cells decreased compared with the control after 24 and 48 hours for interferon alpha-2b concentrations of 1000 and 4000 U/mL, respectively.
  
  
  CONCLUSIONS
  Interferon alpha-2b inhibits the growth and DNA synthesis of endometrioma cells in culture. This finding may have prospects for the treatment of endometriosis.
authors.affiliation: Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, State University of New York Upstate Medical University, Syracuse, New York 13210, USA. badawys@upstate.edu
authors.forename: S Z
authors.initials: SZ
authors.lastname: Badawy
authors.forename: A
authors.initials: A
authors.lastname: Etman
authors.forename: V
authors.initials: V
authors.lastname: Cuenca
authors.forename: A
authors.initials: A
authors.lastname: Montante
authors.forename: L
authors.initials: L
authors.lastname: Kaufman
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002478:Cells, Cultured; D004247:DNA / Q000096:biosynthesis; D004715:Endometriosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D011994:Recombinant Proteins
chemical_list: D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D004247:DNA